Intellia Thera CS (NTLA) Stock Price, Quote & News

Company Profile

Intellia Therapeutics, Inc. operates as a clinical-stage genome editing company focused on developing potentially curative therapeutics using CRISPR/Cas9-based technologies. The company offers clustered, regularly interspaced short palindromic repeats (CRISPR)/CRISPR associated 9 (Cas9) technology for genome editing. The company provides a modular platform, to advance in vivo and ex vivo therapies for diseases. The company's in vivo product candidates include nexiguran ziclumeran, or NTLA-20...

Industry: Biotechnology

Sector: Healthcare

Phone: 857 285 6200

Website: www.intelliatx.com

Address:

40 Erie Street, Suite 130, Cambridge, United States

GSP Jul. 14 at 11:28 PM

$CLRO $SKIN $SPCX $QNT $NTLA

0 · Reply

Steelman111 Jul. 14 at 10:12 PM

$NTLA we will get there be patient.

0 · Reply

stuntman9883 Jul. 14 at 7:10 PM

$NTLA buying here so i can sell at 33

0 · Reply

GoodTidings Jul. 14 at 5:58 PM

$NTLA Last opportunity to buy at trading range support level and join breaking resistance and go up from there... 😎😎😎

0 · Reply

GoodTidings Jul. 14 at 5:25 PM

$NTLA Bears covering during this dip which will give it a smooth break through our last rejected resistance... 😎😎😎

0 · Reply

GoodTidings Jul. 14 at 4:57 PM

$NTLA Doubled my position in this dip... 😎😎😎

0 · Reply

Cheesyisi Jul. 14 at 4:35 PM

$NTLA let‘s go

1 · Reply

MoonkidSamwise Jul. 14 at 4:23 PM

$NTLA Perhaps I managed to utilize this dip. I did sold all at 16ish, and bought back at mid-13. Not perfect, but good enough. And so my position increased by approx 15% with same capital.

0 · Reply

Shirzo Jul. 14 at 4:16 PM

$NTLA

0 · Reply

Steelman111 Jul. 14 at 3:26 PM

$NTLA trying hard to go up today but constantly pushed back down. $1 .5 would be great for today's close.

0 · Reply

Intellia Therapeutics price target raised to $17 from $12 at Wedbush

ALNY AZN IONS

Jul 6, 2026, 4:05 PM EDT - 8 days ago

Intellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2026-06-17T16:06:29.000Z - 27 days ago

Intellia Therapeutics rises 12.9%

2026-06-17T14:07:55.000Z - 27 days ago

Intellia Therapeutics rises 10.7%

2026-06-14T20:35:58.000Z - 4 weeks ago

Intellia Therapeutics presents additional results from Phase 3 HAELO trial

Jun 13, 2026, 7:30 AM EDT - 4 weeks ago

Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Jun 9, 2026, 9:00 AM EDT - 5 weeks ago

Intellia Therapeutics Transcript: AGM 2026

Jun 3, 2026, 4:55 PM EDT - 5 weeks ago

Intellia Therapeutics Transcript: Jefferies Global Healthcare Conference 2026

Jun 1, 2026, 7:30 AM EDT - 6 weeks ago

Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran (lonvo-z) in Late-Breaking Oral Presentation at EAACI 2026

May 20, 2026, 2:35 PM EDT - 7 weeks ago

Intellia Therapeutics Transcript: RBC Capital Markets Global Healthcare Conference 2026

2026-05-13T10:34:18.000Z - 2 months ago

Intellia Therapeutics price target raised to $17 from $13 at Bernstein

2026-05-13T10:28:35.000Z - 2 months ago

Intellia Therapeutics price target lowered to $25 from $30 at H.C. Wainwright

May 12, 2026, 6:40 PM EDT - 2 months ago

Intellia Therapeutics Transcript: Bank of America Global Healthcare Conference 2026

2026-05-12T16:07:18.000Z - 2 months ago

Intellia Therapeutics price target lowered to $19 from $20 at BofA

2026-05-12T11:12:55.000Z - 2 months ago

Intellia Therapeutics price target lowered to $49 from $58 at Canaccord

2026-05-11T17:26:11.000Z - 2 months ago

Intellia Therapeutics reports Q1 EPS (81c), consensus (90c)

May 11, 2026, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Announces First Quarter 2026 Financial Results and Business Updates

May 11, 2026, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Earnings release: Q1 2026

May 11, 2026, 7:30 AM EDT - 2 months ago

Intellia Therapeutics Quarterly report: Q1 2026

May 5, 2026, 7:30 AM EDT - 2 months ago

Intellia Therapeutics to Participate in Upcoming Investor Conferences

2026-05-02T00:11:02.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 141K shares of Intellia Therapeutics today

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Proxy statement: Proxy filing

Apr 30, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Proxy statement: Proxy filing

2026-04-30T03:26:02.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 2.4M shares of Intellia Therapeutics today

2026-04-29T15:02:56.000Z - 2 months ago

Intellia Therapeutics 16.7M share Secondary priced at $10.75

Apr 29, 2026, 7:00 AM EDT - 2 months ago

Intellia Therapeutics Announces Pricing of Public Offering of Common Stock

2026-04-29T00:13:03.000Z - 2 months ago

Cathie Wood’s ARK Investment buys 596K shares of Intellia Therapeutics today

2026-04-28T13:00:00.000Z - 2 months ago

Cathie Wood Offloads Rocket Lab Stock (RKLB) Despite 3% Jump, Buys the Dip in Intellia (NTLA)

ARKG ARKK ARKQ RKLB

2026-04-28T11:21:47.000Z - 2 months ago

Intellia Therapeutics price target raised to $13 from $7 at Baird

2026-04-28T11:12:55.000Z - 2 months ago

Intellia Therapeutics price target raised to $58 from $48 at Canaccord

Apr 27, 2026, 4:01 PM EDT - 2 months ago

Intellia Announces Proposed Public Offering of Common Stock

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Transcript: Study result

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Press release: Study result

Apr 27, 2026, 8:00 AM EDT - 2 months ago

Intellia Therapeutics Slides: Study result

Apr 27, 2026, 7:06 AM EDT - 2 months ago

Intellia Therapeutics' rare genetic disorder therapy meets main goal in trial

Apr 27, 2026, 7:01 AM EDT - 2 months ago

Intellia Therapeutics says its Crispr-based treatment succeeds in pivotal trial

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Intellia Therapeutics Initiates Rolling Submission of Biologics License Application to FDA for Lonvoguran Ziclumeran (lonvo-z) as a One-Time Treatment for Hereditary Angioedema

Apr 27, 2026, 7:00 AM EDT - 2 months ago

Intellia Therapeutics Reports Positive Phase 3 Results in Hereditary Angioedema, Marking a Global First for In Vivo Gene Editing

Apr 24, 2026, 4:05 PM EDT - 2 months ago

Intellia Therapeutics to Report Topline Data from Global Phase 3 HAELO Clinical Trial of Lonvoguran Ziclumeran in Hereditary Angioedema on April 27, 2026

Mar 9, 2026, 8:40 AM EDT - 4 months ago

Intellia Therapeutics Transcript: Leerink Global Healthcare Conference 2026

Mar 3, 2026, 1:10 PM EST - 4 months ago

Intellia Therapeutics Transcript: TD Cowen 46th Annual Health Care Conference

Mar 3, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics Presents Longer-Term Clinical Data for Lonvoguran Ziclumeran (lonvo-z); Hereditary Angioedema (HAE) Patient-Focused Research at AAAAI 2026

Mar 2, 2026, 7:40 AM EST - 4 months ago

US FDA lifts clinical hold on Intellia's heart disease gene therapy trial

Mar 2, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM

Feb 26, 2026, 8:00 AM EST - 4 months ago

Intellia Therapeutics Earnings Call Transcript: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Intellia Therapeutics Annual report: Q4 2025

Feb 26, 2026, 8:00 AM EST - 4 months ago

Intellia Therapeutics Earnings release: Q4 2025

Feb 26, 2026, 7:30 AM EST - 4 months ago

Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Feb 19, 2026, 7:30 AM EST - 5 months ago

Intellia Therapeutics to Hold Conference Call to Discuss Fourth Quarter and Full-Year 2025 Financial Results and Business Updates

Jan 27, 2026, 8:13 AM EST - 6 months ago

US FDA lifts clinical hold on Intellia's nerve disease trail

Jan 14, 2026, 12:00 PM EST - 6 months ago

Intellia Therapeutics Transcript: 44th Annual J.P. Morgan Healthcare Conference

Jan 8, 2026, 7:00 AM EST - 6 months ago

Intellia Therapeutics Slides: Corporate presentation

Jan 7, 2026, 7:30 AM EST - 6 months ago

Intellia Therapeutics to Present at the 44th Annual J.P. Morgan Healthcare Conference

Nov 10, 2025, 3:17 PM EST - 8 months ago

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy

Nov 8, 2025, 5:13 PM EST - 8 months ago

Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema

Nov 6, 2025, 9:30 AM EST - 8 months ago

Intellia Therapeutics Quarterly report: Q3 2025

Nov 6, 2025, 9:30 AM EST - 8 months ago

Intellia Therapeutics Earnings release: Q3 2025

Oct 29, 2025, 5:11 PM EDT - 9 months ago

US FDA places clinical hold on Intellia's two gene-editing treatment trials

Oct 27, 2025, 8:30 AM EDT - 9 months ago

Intellia Therapeutics Transcript: Study Update

Oct 27, 2025, 8:30 AM EDT - 9 months ago

Intellia Therapeutics Press release: Study Update

Oct 27, 2025, 7:38 AM EDT - 9 months ago

Intellia pauses late-stage trials of gene-editing treatment after serious liver event

Oct 27, 2025, 7:30 AM EDT - 9 months ago

Intellia Therapeutics Provides Update on MAGNITUDE Clinical Trials of Nexiguran Ziclumeran (nex-z)

Sep 30, 2025, 7:00 AM EDT - 10 months ago

Intellia Therapeutics Slides: Company Presentation

Sep 25, 2025, 9:52 AM EDT - 10 months ago

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

Sep 18, 2025, 7:30 AM EDT - 10 months ago

Intellia Therapeutics Completes Enrollment in the Global Phase 3 HAELO Study of Lonvoguran Ziclumeran (lonvo-z) for Hereditary Angioedema

Sep 1, 2025, 8:43 AM EDT - 11 months ago

Why big players are pouring millions in THIS biotech stock

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q2 2025

Aug 7, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q2 2025

Aug 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Jul 31, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss Second Quarter 2025 Earnings and Company Updates

Jun 15, 2025, 10:45 AM EDT - 1 year ago

Intellia Therapeutics Announces Positive Three-Year Data from Phase 1 Trial of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema (HAE) at the European Academy of Allergy and Clinical Immunology Congress

Jun 11, 2025, 9:00 AM EDT - 1 year ago

Intellia Therapeutics Transcript: AGM 2025

May 18, 2025, 7:25 AM EDT - 1 year ago

Intellia Announces Positive Two-Year Follow-Up Data from Ongoing Phase 1 Study of Nexiguran Ziclumeran (nex-z), in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy at Peripheral Nerve Society Annual Meeting

May 13, 2025, 7:20 PM EDT - 1 year ago

Intellia Therapeutics Transcript: BofA Securities 2025 Healthcare Conference

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings Call Transcript: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Quarterly report: Q1 2025

May 8, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Earnings release: Q1 2025

May 7, 2025, 7:00 AM EDT - 1 year ago

Intellia Therapeutics Slides: Corporate Presentation

May 1, 2025, 7:30 AM EDT - 1 year ago

Intellia Therapeutics to Hold Conference Call to Discuss First Quarter 2025 Earnings and Company Updates

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 30, 2025, 8:00 AM EDT - 1 year ago

Intellia Therapeutics Proxy statement: Proxy Filing

Apr 23, 2025, 9:50 AM EDT - 1 year ago

Lawsuit for Investors in shares of Intellia Therapeutics, Inc. (NASDAQ: NTLA) announced by the Shareholders Foundation

Apr 14, 2025, 10:58 AM EDT - 1 year ago

Final Deadline Today for the Intellia Therapeutics, Inc. Securities Lawsuit - Contact the DJS Law Group to Discuss Your Rights - NTLA

GSP Jul. 14 at 11:28 PM

$CLRO $SKIN $SPCX $QNT $NTLA

0 · Reply

Steelman111 Jul. 14 at 10:12 PM

$NTLA we will get there be patient.

0 · Reply

stuntman9883 Jul. 14 at 7:10 PM

$NTLA buying here so i can sell at 33

0 · Reply

GoodTidings Jul. 14 at 5:58 PM

$NTLA Last opportunity to buy at trading range support level and join breaking resistance and go up from there... 😎😎😎

0 · Reply

GoodTidings Jul. 14 at 5:25 PM

$NTLA Bears covering during this dip which will give it a smooth break through our last rejected resistance... 😎😎😎

0 · Reply

GoodTidings Jul. 14 at 4:57 PM

$NTLA Doubled my position in this dip... 😎😎😎

0 · Reply

Cheesyisi Jul. 14 at 4:35 PM

$NTLA let‘s go

1 · Reply

MoonkidSamwise Jul. 14 at 4:23 PM

$NTLA Perhaps I managed to utilize this dip. I did sold all at 16ish, and bought back at mid-13. Not perfect, but good enough. And so my position increased by approx 15% with same capital.

0 · Reply

Shirzo Jul. 14 at 4:16 PM

$NTLA

0 · Reply

Steelman111 Jul. 14 at 3:26 PM

$NTLA trying hard to go up today but constantly pushed back down. $1 .5 would be great for today's close.

0 · Reply

blue81 Jul. 14 at 2:46 PM

$NTLA We need to get through August to see that there is no increase in liver enzymes in the aTTR trial. If everything goes smoothly and Antilia doesn't publish some negative news in the third quarter, the market will immediately give them $24 and closethe gap

0 · Reply

De_Monitor Jul. 14 at 2:22 PM

$NTLA bought Intellia again for a new upswing. Results Lonvo-z are comming!

0 · Reply

Nomoneynotalk Jul. 14 at 1:50 PM

$NTLA How I'm feeling about this ...

0 · Reply

the_end Jul. 14 at 12:50 PM

$NTLA well not even a day at 12.xx ... and warsh saying inflation will be a thing of a last soon .... this will launch

0 · Reply

GSP Jul. 14 at 11:36 AM

$CLRO $SKIN $SPCX $QNT $NTLA

0 · Reply

GoodTidings Jul. 14 at 10:43 AM

$NTLA Dont forget that we are around this price range is that there are short parties who are around 50 million shares short who are hell bent doing price manipulation to cover their... So take advantage for as long as it keeps in these lower price range... 😎😎😎

0 · Reply

Kingnev Jul. 14 at 9:14 AM

$NTLA

0 · Reply

Michaelthoaicaonguyen Jul. 14 at 3:41 AM

$ABAT $IXHL $NTLA $SLNH 730am tomorrow central bank chairman will report CPI. Looks like it will be a cool CPI instead of a hot CPI. We should see a moderate rally to the market IMO. This war is put us investors in a choke hold. Constant roller coaster ride. But what can we do. Load or hold on the dip. No need to be emotional. Been here before. Doesn’t this reminds you of last year when Trump announce tariffs. And what happen we recovered. Until the market decided to rerate everything. Oh well what can we do. Patience and patience and more patience, until we fly. When will we fly? Gotta ask Trump.

1 · Reply

GSP Jul. 13 at 8:47 PM

Here are the Final 5 Stocks in Your Day Trading Watch List for July 14th in About 3 Minutes: $CLRO $SKIN $SPCX $QNT $NTLA .

0 · Reply

Steelman111 Jul. 13 at 8:26 PM

$NTLA would not be a bit surprised to see us up 8% tomorrow.

1 · Reply

GoodTidings Jul. 13 at 7:50 PM

$NTLA The only reason of the seloff is pute technical... Bears take advantage of technical setup... Help price collapse around resistance and now you will see recovery at support giving bears the chance to cover relatively relaxed at support prices under the radar while we wait for BLA milestone and commercialisation... Time is running out bears... 😎😎😎

1 · Reply

accretivewealth Jul. 13 at 6:53 PM

$NTLA watching the recent offering price of 10.75 but also watching $SPCX price level of 135 . If oil shoots back to $100/bbl. gonna be some great opportunities. Even now getting close to some "panic-level" opportunities in select stocks. Watching NTLA, OUST, IONQ, FANUY, SPCX. Still hold about a half-position in NTLA, a very minor amount in IONQ, and a heavy slug of FANUY.

0 · Reply

Market Cap	1.82B
Revenue (ttm)	67.67M
Net Income (ttm)	-412.69M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-609.86%
Debt to Equity Ratio	0.00

Volume	4,052,400
Avg Vol	6,170,002
Day's Range	N/A - N/A
Shares Out	139.72M
Stochastic %K	9%
Beta	1.77
Analysts	Sell
Price Target	$26.00